RT Journal Article
SR Electronic
T1 Wastewater to clinical case (WC) ratio of COVID-19 identifies insufficient clinical testing, onset of new variants of concern and population immunity in urban communities
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.19.22274052
DO 10.1101/2022.04.19.22274052
A1 D’Aoust, Patrick M.
A1 Tian, Xin
A1 Towhid, Syeda Tasneem
A1 Xiao, Amy
A1 Mercier, Elisabeth
A1 Hegazy, Nada
A1 Jia, Jian-Jun
A1 Wan, Shen
A1 Kabir, Md Pervez
A1 Fang, Wanting
A1 Fuzzen, Meghan
A1 Hasing, Maria
A1 Yang, Minqing Ivy
A1 Sun, Jianxian
A1 Plaza-Diaz, Julio
A1 Zhang, Zhihao
A1 Cowan, Aaron
A1 Eid, Walaa
A1 Stephenson, Sean
A1 Servos, Mark R.
A1 Wade, Matthew J.
A1 MacKenzie, Alex E.
A1 Peng, Hui
A1 Edwards, Elizabeth A.
A1 Pang, Xiao-Li
A1 Alm, Eric J.
A1 Graber, Tyson E.
A1 Delatolla, Robert
YR 2022
UL http://medrxiv.org/content/early/2022/04/20/2022.04.19.22274052.abstract
AB Clinical testing has been the cornerstone of public health monitoring and infection control efforts in communities throughout the COVID-19 pandemic. With the extant and anticipated reduction of clinical testing as the disease moves into an endemic state, SARS-CoV-2 wastewater surveillance (WWS) is likely to have greater value as an important diagnostic tool to inform public health. As the widespread adoption of WWS is relatively new at the scale employed for COVID-19, interpretation of data, including the relationship to clinical cases, has yet to be standardized. An in-depth analysis of the metrics derived from WWS is required for public health units/agencies to interpret and utilize WWS-acquired data effectively and efficiently. In this study, the SARS-CoV-2 wastewater signal to clinical cases (WC) ratio was investigated across seven different cities in Canada over periods ranging from 8 to 21 months. Significant increases in the WC ratio occurred when clinical testing eligibility was modified to appointment-only testing, identifying a period of insufficient clinical testing in these communities. The WC ratio decreased significantly during the emergence of the Alpha variant of concern (VOC) in a relatively non-immunized community’s wastewater (40-60% allelic proportion), while a more muted decrease in the WC ratio signaled the emergence of the Delta VOC in a relatively well-immunized community’s wastewater (40-60% allelic proportion). Finally, a rapid and significant decrease in the WC ratio signaled the emergence of the Omicron VOC, likely because of the variant’s greater effectiveness at evading immunity, leading to a significant number of new reported clinical cases, even when vaccine-induced community immunity was high. The WC ratio, used as an additional monitoring metric, complements clinical case counts and wastewater signals as individual metrics in its ability to identify important epidemiological occurrences, adding value to WWS as a diagnostic technology during the COVID-19 pandemic and likely for future pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded and supported by Ontario's Ministry of Environment, Conservation and Parks SARS-CoV-2 surveillance initiative (awarded to the University of Ottawa, the University of Toronto, and the University of Waterloo), by CHEO (Children's Hospital of Eastern Ontario) CHAMO (Children's Hospital Academic Medical Organization) (awarded to Dr. Alex E. MacKenzie) and by CIHR/Alberta Health/Alberta Innovates (awarded to Dr. Xiao-Li Pang).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors